Business Context and Reporting Period
This Form 8-K was filed by Ikena Oncology, Inc. on April 13, 2022, reporting a management appointment effective April 25, 2022. The request metadata identifies Imagenebio, Inc., but the filing names Ikena Oncology, Inc. as the registrant.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial results.
Material Changes
- Jotin Marango, M.D., Ph.D. was appointed Chief Financial Officer and Head of Corporate Development.
- Dr. Marango will become the principal financial officer and principal accounting officer, assuming interim responsibilities previously held by Mark Manfredi and Francisco Oliveira.
- The appointment is effective April 25, 2022.
Compensation, Outlook, and Risks
- Annual base salary: $425,000.
- Target annual bonus: 40% of base salary.
- Equity award: an option to purchase 397,199 common shares at an exercise price equal to fair market value on the grant date.
- The option vests 25% after one year, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued employment.
- Severance provisions apply for qualifying termination without cause or for good reason. In connection with a change in control, benefits include one times base salary, one times target annual bonus, acceleration of time-based equity awards, and up to 12 months of employer-paid COBRA premiums.
- Outside a change in control, qualifying severance includes nine months of base salary plus target incentive compensation and up to nine months of COBRA premium reimbursements.
- Change-in-control payments are subject to modified Section 280G tax cutback provisions.
- The complete employment agreement was expected to be filed as an exhibit to the company’s Form 10-Q for the quarter ended June 30, 2022.
Key Facts to Verify
- Confirm the registrant identity, because the provided metadata differs from the filing.
- Review Exhibit 99.1 for the related press release and any additional biographical or strategic commentary.
- Verify the final employment agreement and the terms of the stock option grant when filed.
- Assess the financial impact of the new executive’s salary, bonus opportunity, equity compensation, and potential severance obligations in subsequent filings.